Tobramycin

CHEMBL1747 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

467.5 g/mol

LogP

-6.2

Phase

4

This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection). It can cause hearing loss and kidney damage, so levels in the blood must be monitored during intravenous use. The inhaled form is used to manage chronic lung infections in cystic fibrosis without the same level of systemic risk.

分子量

467.5000 g/mol

LogP

-6.20

TPSA

268.00 Å²

Lipinski 五规则

不符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Chronic Kidney Disease Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O

InChI

InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

Molecular Formula

C18H37N5O9

HBD / HBA

10 / 14

可旋转键数

6

重原子数

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection). It can cause hearing loss and kidney damage, so levels in the blood must be monitored during intravenous use. The inhaled form is used to manage chronic lung infections in cystic fibrosis without the same level of systemic risk.

Yes, Tobramycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1747. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 36294. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Tobramycin 在 PillFYI 上

结构

快速数据

分子式: C18H37N5O9
同义词: 9

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.